LONA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
LeonaBio Inc (LONA) is not a strong buy at the moment for a beginner investor with a long-term strategy. While there are positive developments in the pipeline and analyst ratings are optimistic, the company's financial performance is weak, and the stock lacks immediate trading signals or strong momentum. For now, it is better to hold and monitor for further developments.
The technical indicators show a mixed picture. The MACD is positive and contracting, indicating some bullish momentum. The RSI is neutral at 64.219, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock is trading below the pivot level of 10.174, with key support at 7.381 and resistance at 12.966.
Analysts have upgraded the stock and see significant upside potential.
The company's financial performance is weak, with no revenue growth and a significant drop in net income (-77% YoY). EPS also dropped to 0, and gross margin remains at 0%. Additionally, there is no significant insider or hedge fund activity, and investor awareness is currently low.
In Q3 2025, LeonaBio reported no revenue growth (0% YoY), a net income drop to -$6.61 million (-77% YoY), and EPS declined to 0 (-100% YoY). The gross margin remained at 0%.
Cantor Fitzgerald initiated coverage with an Overweight rating and a fair valuation of $15, while Mizuho upgraded the stock to Outperform with a $10 price target, citing significant upside potential and optimism around the company's lead asset Lasofoxifene.
